Judgments in Case T-460/13 Sun Pharmaceutical Industries and Ranbaxy v Commission, T- 467/13 Arrow Group and Arrow Generics v Commission, T-469/13 Generics (UK) v Commission, T-470/13 Merck v Commission, T-471/13 Xellia Pharmaceuticals and Alpharma v Commission and T-472/13 Lundbeck v Commission

On the 8 September 2016, the General Court of the European Union confirmed the fines of almost €150 million imposed on several undertakings in the context of an infringement intended to delay the marketing of generic versions of the antidepressant citalopram.

ESO: Background information: Antitrust: Commission welcomes General Court judgments upholding its Lundbeck decision in first pharma pay-for-delay case http://www.europeansources.info/record/antitrust-commission-welcomes-general-court-judgments-upholding-its-lundbeck-decision-in-first-pharma-pay-for-delay-case/

ESO: Background information: Antitrust: Commission sends Statement of Objections to Lundbeck and others for preventing market entry of generic antidepressant medicine http://www.europeansources.info/record/press-release-antitrust-commission-sends-statement-of-objections-to-lundbeck-and-others-for-preventing-market-entry-of-generic-antidepressant-medicine/

---